Shots:
- Celltrion has launched Remdantry (formerly Inflectra) injection, a biosimilar to Remicade (infliximab), which will be launched on April 1, 2025, in Canada & received Health Canada NOC on March 7, 2025
- Remdantry, consisting of a chimeric IgG1 mAb that binds to human TNFα, will share the same DIN as Inflectra. It was approved by Health Canada for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis in 2014, and for Crohn’s disease, fistulizing Crohn’s disease, and ulcerative colitis in 2016
- Celltrion offers CELLTRION CONNECT, a patient support program providing reimbursement guidance, financial assistance, and infusion and nurse support throughout treatment
Ref: Businesswire | Image: Celltrion| Press Release
Related News:- Celltrion launches SteQeyma (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
